As part of the partnership, CMIC will leverage Science 37’s clinical trial operating system (OS), as well as its end-to-end technology platform.
These two services will help CMIC to arrange workflows, generate evidence and match data for decentralised clinical studies worldwide, which will help to expedite study timelines.
According to Science 37, it becomes difficult for subjects to enrol in clinical trials as the biopharmaceutical sponsors are limited by geography and location in a traditional site-based model.
Technology-enabled decentralised clinical studies help in decreasing costs while improving efficiency and allowing more patients to take part in the trials.
CMIC Clinical Operation executive vice-president Yoshihito Kondo said: “With our partnership and utilising the Science 37 operating system and technology platform, we are able to more effectively orchestrate the user experience and workflows for patients, telemedicine investigators and mobile nurses, generate requisite evidence and harmonise data all in one place.
“This partnership will also allow for the smooth conduct of global trials including Japan and/or APAC using a unified platform, which will help with CMIC’s efforts to lead the growth of the developing decentralised clinical trial movements in the East.”
This collaboration will allow CMIC to become part of Science 37’s CRO-Certified network.
The network has been designed to empower CROs by providing commercial support, training and access for successful decentralised clinical studies delivery at scale.
Science 37 CEO David Coman said: “Our technology platform will provide CMIC with the capability to more effectively execute decentralised studies with our operating system, which enables access to patient communities, telemedicine investigators, remote coordinator and connected device networks.”